Gc Biopharma
Gc Biopharma, officially known as Green Cross Biopharma, is a leading biopharmaceutical company headquartered in South Korea (KR). Established in 1967, the company has made significant strides in the biopharmaceutical industry, focusing on the development and production of innovative therapies, particularly in the fields of immunology and infectious diseases. With a strong presence in Asia and expanding operations globally, Gc Biopharma is renowned for its core products, including plasma-derived therapies and vaccines. These offerings are distinguished by their high quality and efficacy, positioning the company as a trusted provider in the healthcare sector. Notable achievements include its commitment to research and development, which has propelled Gc Biopharma to a prominent market position, making it a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Gc Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gc Biopharma's score of 40 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gc Biopharma's reported carbon emissions
In 2023, Gc Biopharma reported total carbon emissions of approximately 64,804,000 kg CO2e. This figure includes about 2,564,000 kg CO2e from Scope 1 emissions, 6,989,000 kg CO2e from Scope 2 emissions, and 10,804,000 kg CO2e from Scope 3 emissions, which encompasses categories such as business travel, purchased goods and services, and waste generated in operations. In 2022, the company recorded total emissions of about 66,854,000 kg CO2e, with Scope 1 emissions at approximately 3,210,000 kg CO2e, Scope 2 emissions at around 7,247,000 kg CO2e, and Scope 3 emissions at about 12,374,000 kg CO2e. For 2021, Gc Biopharma's total emissions were approximately 68,166,000 kg CO2e, comprising about 1,654,000 kg CO2e from Scope 1, 2,913,000 kg CO2e from Scope 2, and 14,362,000 kg CO2e from Scope 3. The company has not disclosed specific reduction targets or initiatives as part of its climate commitments. However, it continues to monitor and report its emissions across all relevant scopes, demonstrating a commitment to transparency in its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 9,651,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 42,240,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gc Biopharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
